Core A: Administration will serve as the Coordinating Center for the entire DIAN project. As such, the specific aims of Core A: Administration are as follows: 1. Organize and coordinate activities and communication of the Cores, subcontractors and clinical performance sites toward achieving the stated goals of DIAN, to include administrative, and budgetary support and monitoring, and problem solving on a continuous basis. 2. With the Clinical Core and the Clinical Coordinating Center, delineate protocols;establish, coordinate and monitor participant recruitment and retention. 3. With the Clinical Core, the Clinical Coordinating Center, the Genetics Core and the Informatics Core, organize and monitor data and tissue collection, and storage. 4. With the Steering Committee and subcommittees, establish policies and procedures regarding: protection of research participants;resource (data, images and tissue) sharing, dissemination, an publications;and future expansion of DIAN to include other sites and languages. 5. Organize and support the DIAN Steering Committee and its subcommittees to include arranging meetings, communication and execution of their decisions. 6. Arrange for periodic external review and advice concerning DIAN goals and progress 7. Arrange for and finance genetic counseling and testing services when desired, and participant travel when necessary for participation.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AG032438-06
Application #
8600217
Study Section
Special Emphasis Panel (ZAG1-ZIJ-1)
Project Start
Project End
2014-06-30
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
6
Fiscal Year
2014
Total Cost
$410,073
Indirect Cost
$280,879
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Ringman, John M; Casado, Maria; Van Berlo, Victoria et al. (2017) A novel PSEN1 (S230N) mutation causing early-onset Alzheimer's Disease associated with prosopagnosia, hoarding, and Parkinsonism. Neurosci Lett 657:11-15
Müller, Stephan; Preische, Oliver; Sohrabi, Hamid R et al. (2017) Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. Sci Rep 7:1225
Bateman, Randall J; Benzinger, Tammie L; Berry, Scott et al. (2017) The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement 13:8-19
Su, Yi; Vlassenko, Andrei G; Couture, Lars E et al. (2017) Quantitative hemodynamic PET imaging using image-derived arterial input function and a PET/MR hybrid scanner. J Cereb Blood Flow Metab 37:1435-1446
Cruchaga, Carlos; Del-Aguila, Jorge L; Saef, Benjamin et al. (2017) Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement :
Natelson Love, Marissa; Clark, David G; Cochran, J Nicholas et al. (2017) Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease. Neurobiol Aging 49:216.e7-216.e13
Reiman, Eric M; Langbaum, Jessica B; Tariot, Pierre N et al. (2016) CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol 12:56-61
Molinuevo, José L; Cami, Jordi; Carné, Xavier et al. (2016) Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. Alzheimers Dement 12:614-22
Ringman, John M; Monsell, Sarah; Ng, Denise W et al. (2016) Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol 75:284-90
Suárez-Calvet, Marc; Araque Caballero, Miguel Ángel; Kleinberger, Gernot et al. (2016) Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8:369ra178

Showing the most recent 10 out of 83 publications